Uses

Indicated to reduce the risk of major adverse cardiovascular events in adults at increased cardiovascular risk, and as an adjunct to diet and exercise to lower LDL-C in adults with hypercholesterolemia and in adults and pediatric patients aged 8 years and older with heterozygous or homozygous familial hypercholesterolemia.

Do not use if

Contraindicated in patients with a history of serious hypersensitivity reaction to alirocumab or any excipient in the formulation, including hypersensitivity vasculitis and angioedema.

Side effects

Common adverse reactions include injection site reactions and influenza in patients with primary hypercholesterolemia, and myalgia in patients with established cardiovascular disease. Hypersensitivity reactions may also occur.

Warnings

Hypersensitivity reactions including vasculitis, angioedema, and reactions requiring hospitalization have been reported; discontinue treatment if serious reactions occur. Assess benefit-risk in patients with severe renal or hepatic impairment.

How it works

Alirocumab is a fully human monoclonal antibody that inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9). By preventing PCSK9 from binding to LDL receptors on hepatocytes, it increases the number of available LDL receptors, thereby enhancing LDL clearance from circulation and significantly reducing LDL-C levels.

Storage

Store refrigerated at 2°C to 8°C in the original carton to protect from light. Do not freeze or shake. If needed, may be kept at room temperature up to 25°C for a limited period as per label instructions.